These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 6143506)

  • 61. Schizophrenic relapse after drug withdrawal is predictable.
    Dencker SJ; Malm U; Lepp M
    Acta Psychiatr Scand; 1986 Feb; 73(2):181-5. PubMed ID: 3705994
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Carbamazepine maintenance treatment in outpatient schizophrenics.
    Carpenter WT; Kurz R; Kirkpatrick B; Hanlon TE; Summerfelt AT; Buchanan RW; Waltrip RW; Breier A
    Arch Gen Psychiatry; 1991 Jan; 48(1):69-72. PubMed ID: 1670617
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Neuroleptic-free intervals in the treatment of schizophrenia.
    Pyke J; Seeman MV
    Am J Psychiatry; 1981 Dec; 138(12):1620-1. PubMed ID: 6118068
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Differences in the EEG profiles of early and late responders to antipsychotic treatment in first-episode, drug-naive psychotic patients.
    Merlo MC; Kleinlogel H; Koukkou M
    Schizophr Res; 1998 Apr; 30(3):221-8. PubMed ID: 9589516
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Justifying neuroleptic drug treatment.
    Overall JE; Garza-Trevino E; Rhoades HM; Volkow ND; Cecil S
    Hosp Community Psychiatry; 1989 Jul; 40(7):749-51. PubMed ID: 2570741
    [No Abstract]   [Full Text] [Related]  

  • 66. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year.
    Jolley AG; Hirsch SR; McRink A; Manchanda R
    BMJ; 1989 Apr; 298(6679):985-90. PubMed ID: 2567190
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparative study of schizophrenic patients relapsed on and off medication.
    Bartkó G; Mayláth E; Herczeg I
    Psychiatry Res; 1987 Nov; 22(3):221-7. PubMed ID: 2893403
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis.
    Uchida H; Suzuki T; Takeuchi H; Arenovich T; Mamo DC
    Schizophr Bull; 2011 Jul; 37(4):788-99. PubMed ID: 19946012
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Response of thyrotropin to thyrotropin-releasing hormone as predictor of treatment outcome. Prediction of recovery and relapse in treatment with antidepressants and neuroleptics.
    Langer G; Koinig G; Hatzinger R; Schönbeck G; Resch F; Aschauer H; Keshavan MS; Sieghart W
    Arch Gen Psychiatry; 1986 Sep; 43(9):861-8. PubMed ID: 2875702
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Electroencephalographic sleep in clinically stable schizophrenic patients: two-weeks versus six-weeks neuroleptic-free.
    Nofzinger EA; van Kammen DP; Gilbertson MW; Gurklis JA; Peters JL
    Biol Psychiatry; 1993 Jun 1-15; 33(11-12):829-35. PubMed ID: 8104041
    [TBL] [Abstract][Full Text] [Related]  

  • 71. How high is the relapse rate in schizophrenia?
    Johnstone EC; Geddes J
    Acta Psychiatr Scand Suppl; 1994; 382():6-10. PubMed ID: 7916528
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Quality of life in schizophrenia: insight and subjective response to neuroleptics.
    Browne S; Garavan J; Gervin M; Roe M; Larkin C; O'Callaghan E
    J Nerv Ment Dis; 1998 Feb; 186(2):74-8. PubMed ID: 9484306
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia.
    van Kammen DP; Kelley ME; Gurklis JA; Gilbertson MW; Yao JK; Peters JL
    Arch Gen Psychiatry; 1995 Aug; 52(8):673-8. PubMed ID: 7543265
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A placebo-controlled trial of trihexyphenidyl in unmedicated patients with schizophrenia.
    Goff DC; Amico E; Dreyfuss D; Ciraulo D
    Am J Psychiatry; 1994 Mar; 151(3):429-31. PubMed ID: 8109654
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Intermittent vs maintenance medication in schizophrenia. Two-year results.
    Herz MI; Glazer WM; Mostert MA; Sheard MA; Szymanski HV; Hafez H; Mirza M; Vana J
    Arch Gen Psychiatry; 1991 Apr; 48(4):333-9. PubMed ID: 1672588
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ceruletide for schizophrenia: a double-blind study.
    Mattes JA; Hom W; Rochford JM; Orlosky M
    Biol Psychiatry; 1985 May; 20(5):533-8. PubMed ID: 2859054
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Untreated psychosis and long-term outcome in schizophrenia.
    Waddington JL; Scully PJ
    Schizophr Bull; 1998; 24(1):34-5. PubMed ID: 9502545
    [No Abstract]   [Full Text] [Related]  

  • 78. Prolactin shifts after neuroleptic withdrawal.
    Green AI; Faraone SV; Brown WA
    Psychiatry Res; 1990 Jun; 32(3):213-9. PubMed ID: 1975101
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine.
    Meltzer HY; Lee MA; Ranjan R; Mason EA; Cola PA
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):176-87. PubMed ID: 8935814
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Research in schizophrenia and the discontinuation of antipsychotic medications.
    Wyatt RJ
    Schizophr Bull; 1997; 23(1):3-9. PubMed ID: 9050108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.